Consumption details of systemically acting antiviral and antimicrobial preparations in period of novel coronavirus infection spread in retail sector of Samara region pharmaceutical market

封面

如何引用文章

详细

An analysis of the medicinal preparation consumption structure in the period of the COVID-19 pandemic in the pharmacy network reflects the existing outpatient practice and makes it possible to draw generalized conclusions about its compliance with the pharmacotherapy standards.

The aim. Comparative analysis of population consumption of antimicrobial and antiviral medicines sold in the retail pharmacies of the Samara region in 2015–2021.

Materials and methods. The study was conducted in the retail sector of the Samara region pharmaceutical market. The material of the study was the information on the list of items and dispensing volumes of antibacterial and individual antiviral drugs during the novel coronavirus infection spread (in 2020) in the network of the Samara region pharmacies. The data are compared with the indicators of the drug sales in 2015–2019. Methods of retrospective, comparative, graphical, methodological, content analyzes and statistical methods of analyses were used.

Results. The authors have established a significant distortion in the consumption of systemic antimicrobial preparations in the Samara region pharmacy segment in the period of 2015–2019 with the predominance of the ATC (Anatomical Therapeutic Chemical Classification System) J01D group, primarily cephalosporins (38%), mainly by the parenteral administration route. The share of macrolides (J01F) consumption in volume terms was 14.9%, of fluoroquinolones (J01M) – 11.3%, beta-lactam antibiotics with beta-lactamase inhibitors – 10.7%, beta-lactam antibiotics penicillins (J01C) – 8.1%. Compared to 2019, in 2020, under the conditions of the COVID-19 pandemic, the total consumption of AMPs increased by 2.1 times. In the “Other beta-lactam antibiotics” group with a predominant proportion of cephalosporins, there was an increase by 3.2 times, in the “Macrolides and lincosamides” group – by 3.5 times, in “Quinolone derivatives” – by 2.6 times. The noted facts should be assessed as the phenomenon that can have a direct impact on the growth of an antibiotic resistance on a population scale. Among antivirals, the largest consumption increase was noted for oseltamivir and rimantadine. In absolute terms, the volume of antiviral preparations consumption in 2020 increased by 2.4 times, which was accompanied by an increase in the cost of one package by 55.8%.

Conclusion. In the period of spreading a novel coronavirus infection, a significant increase in the consumption of antimicrobial and antiviral preparations (up to 20 times for certain pharmacotherapeutic groups and names) was notified, which may negatively affect the growth of the antibiotic resistance in the population.

作者简介

Irina Petrukhina

Samara State Medical University

编辑信件的主要联系方式.
Email: ditrich@samaramail.ru
ORCID iD: 0000-0001-6207-5575

Doctor of Sciences (Pharmacy), Associate Professor, Deputy Director of the Institute of Pharmacy, Head of the Department of Pharmacy Management and Economics

俄罗斯联邦, 89, Chapaevskaya Str., Samara, 443099

Pyotr Lebedev

Samara State Medical University

Email: p.a.lebedev@samsmu.ru
ORCID iD: 0000-0003-3501-2354

Doctor of Sciences (Medicine), Professor, Head of the Department of Therapy at the Institute of Professional Education

俄罗斯联邦, 89, Chapaevskaya Str., Samara, 443099

Ilya Sirotko

Samara State Medical University

Email: i.i.sirotko@samsmu.ru
ORCID iD: 0000-0002-8884-7016

Doctor of Sciences (Medicine), Professor of the Department of Therapy at the Institute of Professional Education

俄罗斯联邦, 89, Chapaevskaya Str., Samara, 443099

Tatyana Ryazanova

Samara State Medical University

Email: t.k.ryazanova@samsmu.ru
ORCID iD: 0000-0002-4581-8610

Candidate of Sciences (Pharmacy), Associate Professor of the Department of Pharmacy Management and Economics

俄罗斯联邦, 89, Chapaevskaya Str., Samara, 443099

Elena Gladunova

Samara State Medical University

Email: e.p.gladunova@samsmu.ru
ORCID iD: 0000-0001-5198-0393

Doctor of Sciences (Pharmacy), Associate Professor, Professor of the Department of Pharmacy Management and Economics

俄罗斯联邦, 89, Chapaevskaya Str., Samara, 443099

Andrey Garanin

Samara State Medical University

Email: a.a.garanin@samsmu.ru
ORCID iD: 0000-0001-6665-1533

Candidate of Sciences (Medicine), Assistant of the Department of Propaedeutic Therapy

俄罗斯联邦, 89, Chapaevskaya Str., Samara, 443099

参考

  1. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–9. doi: 10.1016/j.cmi.2020.07.016
  2. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 Aug;81(2):266–75. doi: 10.1016/j.jinf.2020.05.046
  3. Shishkova VN. [The possibilities of modern drugs in the prevention and treatment of SARS and influenza]. RMJ. 2016;6:395–400. Russian
  4. Sidorenko SV, Yakovlev SV, Spichak TV, Suvorova MP, Rafalskiy VV, Tatochenko VK, Dronov IA, Zakharova IN, Zaplatnikov AL, Geppe NA, Lobzin YuV, Abeuova BA, Boyadzhyan GG, Bakradze MD, Malakhov AB, Mumladze EB, Myrzabekova GT, Ursova NI. [Strategy and tactics of the rational use of antimicrobial drugs in outpatient practice. Eurasian clinical guidelines. 2016]. Consilium Medicum. Pediatrics (Suppl.). 2016; (4): 10–20. Russian
  5. Baranov AA, Bogomilsky MR, Volkov IK, Geppe NA, Kozlov RS, Kozlova LV, Korovina NA, Manerov FK, Mizernitsky YuL, Namazova LS, Nasonova VA, Samsygina GA, Sergeeva TV, Spichak TV, Strachunsky LS, Tatochenko VK, Yakushin SB. [The use of antibiotics in children in outpatient practice: practical recommendations]. Clinical microbiology and antimicrobial chemotherapy. 2007;9(3);200–10. Russian
  6. Gulliford MC, Moore MV, Little P, Hay AD, Fox R, Prevost AT, Juszczyk D, Charlton J, Ashworth M. Safety of reduced antibiotic prescribing for self limiting respiratory tract infections in primary care: cohort study using electronic health records. BMJ. 2016 Jul 4;354:i3410. doi: 10.1136/bmj.i3410
  7. Misurski DA, Lipson DA, Changolkar AK. Inappropriate antibiotic prescribing in managed care subjects with influenza. Am J Manag Care. 2011 Sep;17(9):601–8.
  8. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, Saleem Z, Sneddon J, Hoxha I, Islam S, Mwita J, do Nascimento RCRM, Dias Godói IP, Niba LL, Amu AA, Acolatse J, Incoom R, Sefah IA, Opanga S, Kurdi A, Chikowe I, Khuluza F, Kibuule D, Ogunleye OO, Olalekan A, Markovic-Pekovic V, Meyer JC, Alfadl A, Phuong TNT, Kalungia AC, Campbell S, Pisana A, Wale J, Seaton RA. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life (Basel). 2021 Jun 7;11(6):528. doi: 10.3390/life11060528
  9. Tatochenko VK. [Therapy of acute respiratory infections in children]. RMJ. 2004;(21):1200. Russian
  10. Strathdee SA, Davies SC, Marcelin JR. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396(10257):1050–3. doi: 10.1016/S0140-6736(20)32063-8
  11. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459–68. doi: 10.1093/cid/ciaa530
  12. Crane MA, Popovic A, Panaparambil R, Stolbach AI, Romley JA, Ghanem KG. Reporting of Infectious Diseases in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic. Clin Infect Dis. 2022 Mar 9;74(5):901–4. doi: 10.1093/cid/ciab529
  13. Kozlov RS. [Antimicrobial resistance as a real threat to national security]. RMJ. Medical review. 2014;22(4):321. Russian
  14. Volkova US, Slobodenyuk EV. [Antimicrobals for systemic use in the pharmaceutical market of Khabarovsk]. Pacific Medical Journal. 2014;(2):35–7. Russian
  15. Yakovlev SV. New Concept of Rational Use of Antibiotics in Outpatient Practice. Antibiotics and Chemotherapy. 2019;64(3-4):48–58. doi: 10.24411/0235-2990-2019-100017. Russian
  16. Yakovlev SY, Zhuravleva MV, Protsenko DN, Beloborodov VB, Briko NI. etc. Antibiotic stewardship program for inpatient care. Clinical guidelines for Moscow hospitals. Consilium Medicum. 2017;19(7.1. Surgery):15–51. Russian
  17. Liu JW, Lin SH, Wang LC, Chiu HY, Lee JA. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2119151. doi: 10.1001/jamanetworkopen.2021.19151. Erratum in: JAMA Netw Open. 2021 Oct 1;4(10):e2133433.
  18. Sel’kova EP, Iakovlev VN, Semenenko TA, Filatov NN, Gotvianskaia TP, Danilina GA, Pantiukhova TN, Nikitina GIu, Tur’ianov MKh. Otsenka profilakticheskogo éffekta amiksina v otnoshenii ostrykh respiratornykh virusnykh infektsiĭ [Evaluation of amyxin effect in prophylaxis of acute respiratory viral infections]. Zh. Mikrobiol. Epidemiol. Immunobiol. 2001 May-Jun;(3):42–6.
  19. Ekins S, Lane TR, Madrid PB. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond. Pharm Res. 2020 Mar 25;37(4):71. doi: 10.1007/s11095-020-02799-8. Erratum in: Pharm Res. 2020 Nov 6;37(12):239.
  20. Semenenko TA, Selkova EP, Nikitina GY, Gotvyanskaya TP, Yudina TI, Amaryan MP, Nosik NN, Turyanov MH. Immunomodulators in the prevention of acute respiratory viral infections. Russ J Immunol. 2002 Jul;7(2):105–14.
  21. Zakirov IG. Opyt primeneniia amiksina pri lechenii i profilaktike nekotorykh virusnykh infektsionnykh zabolevaniĭ [Use of amixin in the therapy and prevention of some viral infections]. Klin Med (Mosk). 2002;80(12):54–6. Russian
  22. Leneva IA, Fedyakina IT, Eropkin MUб Gudova NV, Romanovskaya AA, Danilenko DM, Vinogradova SMб Lepeshkin AYu, Shestopalov AM. [To study the antiviral activity of domestic anti-influenza chemotherapy drugs in cell culture and on animal models]. Questions of virology. 2010;3:19–25. Russian
  23. Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019 Aug;36(8):1878–905. doi: 10.1007/s12325-019-00995-6
  24. Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648. doi: 10.1186/s12879-016-1965-5
  25. Leneva IA, Pshenichnaya NY, Bulgakova VA. Umifenovir and coronavirus infections: a review of research results and clinical practice. Terapevticheskii arkhiv. 2020;92(11):91–7. doi: 10.26442/00403660.2020.11.000713
  26. Alavi Darazam I, Shokouhi S, Mardani M, Pourhoseingholi MA, Rabiei MM, Hatami F, Shabani M, Moradi O, Gharehbagh FJ, Irvani SSN, Amirdosara M, Hajiesmaeili M, Rezaei O, Khoshkar A, Lotfollahi L, Gachkar L, Dehbsneh HS, Khalili N, Soleymaninia A, Kusha AH, Shoushtari MT, Torabinavid P. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int Immunopharmacol. 2021 Oct;99:107969. doi: 10.1016/j.intimp.2021.107969

补充文件

附件文件
动作
1. JATS XML
2. Figure 1 – Dynamics of realized demand for some groups of antibacterial medicinal preparations, pandemic sales of which increased

下载 (84KB)
3. Figure 2 – Dynamics of realized demand for some groups of antibacterials, sales of which decreased or did not change during pandemic

下载 (108KB)
4. Figure 3 – Median shares of realized demand volume for antibacterial MPs in 2015–2021

下载 (95KB)
5. Figure 4 – Dynamics of demand for ATC subgroup medicinal preparations – J01D “Other beta-lactam antibacterials” in 2015–2021 (by months)

下载 (106KB)
6. Figure 5 – Dynamics of demand for ATC subgroup medicinal preparations – J01F "Macrolides, lincosamides and streptogramins" in 2015–2021 (by months)

下载 (98KB)
7. Figure 6 – Median volume shares of realized demand for antiviral medicinal preparations in 2015–2020

下载 (77KB)
8. Figure 7 – Incidence of acute respiratory viral infections, influenza, COVID-19, community-acquired pneumonia in 2019 (according to Samara region Rospotrebnadzor), volumes of realized antiviral MPs and AMPs packages

下载 (114KB)
9. Figure 8 – The incidence of acute respiratory viral infections, influenza, COVID-19, community-acquired pneumonia in 2020 (according to Samara region Rospotrebnadzor), volumes of realized of antiviral MPs and AMPs packages

下载 (116KB)
10. Figure 9 – Dynamics of oseltamivir demand in 2015–2021

下载 (85KB)
11. Figure 10 – Dynamics of rimantadine demand in 2015–2020

下载 (132KB)
12. Figure 11 – Dynamics of imidazolylethanamide pentadioic acid demand in 2015–2020

下载 (127KB)
13. Figure 12 – Dynamics of thyrolon demand in 2015–2020

下载 (121KB)
14. Figure 13 – Dynamics of umifenovir demand in 2015–2020

下载 (108KB)

版权所有 © Petrukhina I., Lebedev P., Sirotko I., Ryazanova T., Gladunova E., Garanin A., 2023

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 
##common.cookie##